Showing results (191-200 of 258) with videos related to

Sort By:
Pageof 26
Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.
Frontiers in Oncology|December 2, 2022
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experienceRossella Iula, Danilo De Novellis, Fabio Trastulli, et al.
Pharmaceuticals (Basel, Switzerland)|April 26, 2025
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID StudyNicola Sgherza, Olga Battisti, Paola Curci, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 13, 2017
Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose CyclophosphamideAnna Maria Raiola, Antonio Risitano, Nicoletta Sacchi, et al.
Blood|June 14, 2012
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysisSimona Luatti, Fausto Castagnetti, Giulia Marzocchi, et al.
Current Medical Research and Opinion|January 18, 2021
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real lifeFiorenzo Santoleri, Elena Ranucci, Gaetano La Barba, et al.
Blood|March 7, 2009
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet StudyMichele Baccarani, Gianantonio Rosti, Fausto Castagnetti, et al.
Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Hemasphere|December 31, 2025
Health-related quality of life and symptom profile of patients with BCR::ABL1-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational studyGiovanni Caocci, Alessandro Costa, Francesca Palandri, et al.
Blood|July 20, 2002
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemiaAgostino Tafuri, Chiara Gregorj, Maria T Petrucci, et al.
Pageof 26